Astrazeneca Entered Into An Exclusive License Agreement With CSPC Pharmaceutical Group To Advance The Development Of An Early Stage, Novel Small Molecule Lipoprotein (A) (LP(A)) Disruptor
Astrazeneca Entered Into An Exclusive License Agreement With CSPC Pharmaceutical Group To Advance The Development Of An Early Stage, Novel Small Molecule Lipoprotein (A) (LP(A)) Disruptor
AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.
阿斯利康已與CSPC藥品集團有限公司(CSPC)簽訂獨家許可協議，推進早期小分子脂蛋白(a)(Lp(a))破壞劑的開發，該藥物有潛力爲患有血脂異常的患者提供額外好處。這一資產進一步強化了公司的心血管產品組合，有助於應對主要驅動慢性心血管疾病的主要風險因素。
Under the terms of the agreement, AstraZeneca will receive access to CSPC's pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibitor, AZD0780.
根據協議條款，阿斯利康將獲得CSPC的臨床前候選小分子YS2302018，一種口服Lp(a)破壞劑，旨在將其開發爲一種新型降脂療法，在心血管疾病領域以及單獨或與口服小分子PCSK9抑制劑AZD0780組合的多種心血管疾病適應症中發揮潛力。
